Status:

RECRUITING

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

Lead Sponsor:

Zhujiang Hospital

Conditions:

Hepatocellular Carcinoma Resectable

Eligibility:

All Genders

18-75 years

Brief Summary

This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudin...

Detailed Description

The recurrence rate of hepatocellular carcinoma after curative treatment is high, and the minimal residual disease(MRD) in patients is the major cause of liver cancer recurrence, and the MRD is an imp...

Eligibility Criteria

Inclusion

  • Male or female patients aged 18-75 years;
  • Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery;
  • ECOG physical status score is 0-1;
  • Child-Pugh score is 5-6 points (Level A);
  • Not received any anti-tumor therapy;
  • Laboratory tests were at normal levels within 7 days before enrollment.

Exclusion

  • Patient can't provide blood samples for ctDNA testing;
  • Patient with two or more types of tumors at the same time;
  • Non-primary liver lesions;
  • Pregnant or lactating women;
  • Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;
  • Patient with serious heart disease;
  • Other conditions deemed unsuitable for inclusion by the researcher.

Key Trial Info

Start Date :

November 20 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 30 2026

Estimated Enrollment :

255 Patients enrolled

Trial Details

Trial ID

NCT06157060

Start Date

November 20 2023

End Date

December 30 2026

Last Update

March 28 2024

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

The Sixth Affiliated Hospital of South China University of Technology

Foshan, Guangdong, China

2

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China, 510220

3

Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, Guangdong, China

4

Guangdong Provincial Hospital of Traditional Chinese Medicine

Guangzhou, Guangdong, China

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA | DecenTrialz